McKessonの空売り状況は、投資家がMcKessonの株価下落に賭けている度合いを知ることができます。空売りデータは2週間ごとに更新されます。

McKesson (NYSE:MCK) 株価情報, 空売り情報

McKesson

McKesson Corp is one of three leading pharmaceutical wholesalers in the us engaged in sourcing and distributing branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail order), hospitals networks, and healthcare providers. Along with Cencora and Cardinal Health, the three account for over 90% of the us pharmaceutical wholesale industry. Outside the us market, McKesson engages in pharmaceutical wholesale and distribution in Canada. Additionally, the company supplies medical-surgical products and equipment to healthcare facilities and provides a variety of technology solutions for pharmacies.

McKesson Corp

MALLINCKRODT PB LTD CO by Mallinckrodt plc.

Mallinckrodt PLC

Jade Leader Corp

MCKESSON ORD

McKesson Europe AG ADR

After Wednesday&#8217;s &#8220;everything rally&#8221; spurred by the election results, investors took a less euphoric approach on Thursday ahead of the Federal Open Market Committee (FOMC) meeting.
The Fed is widely expected to cut interest rates by 25 basis points, bringing them to a range of 4.5%-4.75%, following a previous 50-basis-point cut in September.
Yet, all eyes are on Fed Chair Jerome Powell&#8217;s comments at 2:30 p.m. ET regarding the potential for future rate hikes and his views on inflation risks. Concerns from the market center on the possibility of a policy U-turn driven by higher fiscal deficits and price pressures from trade tariffs under a Trump administration.
Tech stocks led gains, with the Nasdaq 100 extending its record-breaking levels, surpassing 21,000 points and eyeing a third consecutive positive session. The S&amp;P 500 and Dow Jones posted more modest gains, while the Russell 2000 paused after Wednesday&#8217;s 5.8% leap.
Tesla Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) remained a top performer among mega-cap stocks, bolstered by expectations of Elon Musk&#8216;s influence in the upcoming administration.
Treasury yields reversed a substantial portion of Wednesday's post-election increase, while the U.S. dollar dipped by 0.7%.
Metal commodities rebounded after Wednesday&#8217;s sharp losses, with gold rising 1.3%, silver up 2% and copper rallying over 4%.
Oil prices strengthened by 1%, with West Texas Intermediate trading around $72 per barrel.
Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) rose 0.8%, reaching $76,000 to extend its record highs, while Ethereum (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/eth/usd">ETH</a>) outperformed with a gain of over 4%.
<h1 class="wp-block-heading">Thursday&#8217;s Performance In Major U.S. Indices, ETFs</h1>
<figure class="wp-block-table is-style-stripes"> 
<table>
<tbody>
<tr>
<td>Major Indices</td>
<td>Price</td>
<td>1-day % chg</td>
</tr>
<tr>
<td>Nasdaq 100</td>
<td>21,050.78</td>
<td>1.3%</td>
</tr>
<tr>
<td>S&amp;P 500</td>
<td>5,968.27</td>
<td>0.7%</td>
</tr>
<tr>
<td>Dow Jones</td>
<td>43,748.20</td>
<td>0.0%</td>
</tr>
<tr>
<td>Russell 2000</td>
<td>2,389.10</td>
<td>-0.2%</td>
</tr>
</tbody>
</table>
</figure>
According to <a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent110624&amp;t=be2bearmibe3na1">Benzinga Pro</a> data:
<ul>
<li>The&nbsp;SPDR S&amp;P 500 ETF Trust&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) rose 0.7% to $594.84.</li>
<li>The&nbsp;SPDR Dow Jones Industrial Average&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DIA#NYSE">DIA</a>)&nbsp;stalled at $437.25.</li>
<li>The tech-heavy Invesco QQQ Trust Series (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>) soared 1.3% to $512.38.</li>
<li>The iShares Russell 2000 ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IWM#NYSE">IWM</a>) eased 0.3% to $236.67.</li>
<li>The Technology Select Sector SPDR Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLK#NYSE">XLK</a>) outperformed, rising 1.3%. The Financials Select Sector SPDR Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLF#NYSE">XLF</a>) lagged, down 1.2%.</li>
</ul>
<h1 class="wp-block-heading">Thursday&#8217;s Stock Movers</h1>
Some relevant reactions to earnings reports are:
<ul>
<li>Qualcomm Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QCOM#NASDAQ">QCOM</a>), up 0.1%, </li>
<li>Gilead Sciences Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GILD#NASDAQ">GILD</a>), up 6.2%, </li>
<li>MercadoLibre Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MELI#NASDAQ">MELI</a>), down 16%, </li>
<li>APPLovin Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APP#NASDAQ">APP</a>), up 43%, </li>
<li>McKesson Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MCK#NYSE">MCK</a>), up 11%, </li>
<li>Take-Two Interactive Software Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TTWO#NASDAQ">TTWO</a>), up 6.3%, </li>
<li>Transdigm Group Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TDG#NYSE">TDG</a>), down 4.4%</li>
</ul>
Read Next:
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/11/41814589/why-trumps-boost-to-treasury-yields-inflation-expectations-may-weaken-feds-efforts-">Why Trump&#8217;s Boost To Treasury Yields, Inflation Expectations May Weaken Fed&#8217;s Efforts To Cut Interest Rates</a></li>
</ul>
This image was created using artificial intelligence.

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

Equities

Large Cap

Macro Economic Events

Sector ETFs

Broad U.S. Equity ETFs

Commodities

Economics

Federal Reserve

Tech

ETFs

$BTC

$ETH

SPDR Dow Jones Industrial Average ETF Trust

GILD

MELI

QCOM

TSLA

TTWO

XLRE

Nasdaq 100 Extends Record Levels Ahead Of Fed Meeting, Tesla Hits 26-Month Highs, Small Caps Stall: What's Driving Markets Thursday?

Investors with a lot of money to spend have taken a bullish stance on McKesson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MCK#NYSE">MCK</a>).
And retail traders should know.
We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga.
Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with MCK, it often means somebody knows something is about to happen.
So how do we know what these investors just did? 
Today, <a href="https://pro.benzinga.com/?utm_source=insights">Benzinga</a>'s options scanner spotted 11 uncommon options trades for McKesson.
This isn't normal.
The overall sentiment of these big-money traders is split between 36% bullish and 36%, bearish.
Out of all of the special options we uncovered, 4 are puts, for a total amount of $204,282, and 7 are calls, for a total amount of $211,877.
<h3>Projected Price Targets</h3>
Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $340.0 to $610.0 for McKesson over the last 3 months. 
<h3>Volume &amp; Open Interest Trends</h3>
Examining the volume and open interest provides crucial insights into stock research. This information is key in gauging liquidity and interest levels for McKesson's options at certain strike prices. Below, we present a snapshot of the trends in volume and open interest for calls and puts across McKesson's significant trades, within a strike price range of $340.0 to $610.0, over the past month.
<h3>McKesson Call and Put Volume: 30-Day Overview</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1730997923_0.png" alt="Options Call Chart" />
<h3>Significant Options Trades Detected:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th align="right">Open Interest</th>
<th align="right">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>MCK</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>06/20/25</td>
<td>$17.8</td>
<td>$14.0</td>
<td>$14.5</td>
<td>$520.00</td>
<td>$75.4K</td>
<td align="right">32</td>
<td align="right">83</td>
</tr>
<tr>
<td>MCK</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>06/20/25</td>
<td>$16.9</td>
<td>$13.7</td>
<td>$14.0</td>
<td>$520.00</td>
<td>$56.0K</td>
<td align="right">32</td>
<td align="right">123</td>
</tr>
<tr>
<td>MCK</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>06/20/25</td>
<td>$17.8</td>
<td>$14.5</td>
<td>$14.5</td>
<td>$520.00</td>
<td>$44.9K</td>
<td align="right">32</td>
<td align="right">31</td>
</tr>
<tr>
<td>MCK</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>01/16/26</td>
<td>$187.0</td>
<td>$178.0</td>
<td>$181.93</td>
<td>$450.00</td>
<td>$36.3K</td>
<td align="right">46</td>
<td align="right">2</td>
</tr>
<tr>
<td>MCK</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>11/08/24</td>
<td>$37.3</td>
<td>$32.1</td>
<td>$34.0</td>
<td>$565.00</td>
<td>$33.9K</td>
<td align="right">159</td>
<td align="right">124</td>
</tr>
</tbody>
</table>

<h3>About McKesson</h3>
McKesson Corp is one of three leading pharmaceutical wholesalers in the us engaged in sourcing and distributing branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail order), hospitals networks, and healthcare providers. Along with Cencora and Cardinal Health, the three account for over 90% of the us pharmaceutical wholesale industry. Outside the us market, McKesson engages in pharmaceutical wholesale and distribution in Canada. Additionally, the company supplies medical-surgical products and equipment to healthcare facilities and provides a variety of technology solutions for pharmacies.
Following our analysis of the options activities associated with McKesson, we pivot to a closer look at the company's own performance.
<h3>McKesson's Current Market Status</h3>
<ul>
<li>Currently trading with a volume of 1,075,384, the MCK's price is up by 10.26%, now at $605.65. </li>
<li>RSI readings suggest the stock is currently may be overbought.</li>
<li>Anticipated earnings release is in 90 days.</li>
</ul>
<h3>What The Experts Say On McKesson</h3>
Over the past month, 2 industry analysts have shared their insights on this stock, proposing an average target price of $684.0.
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; In a positive move, an analyst from Baird has upgraded their rating to Outperform and adjusted the price target to $688. 
&#x2A; An analyst from Evercore ISI Group has decided to maintain their Outperform rating on McKesson, which currently sits at a price target of $680. 
Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for McKesson with <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> for real-time alerts.

Options

Markets

Spotlight on McKesson: Analyzing the Surge in Options Activity

U.S. stocks were higher, with the Nasdaq Composite gaining around 200 points on Thursday.
Shares of HubSpot, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HUBS#NYSE">HUBS</a>) rose sharply during Thursday's session after the company reported better-than-expected third-quarter financial results and issued FY24 <a href="https://www.benzinga.com/news/earnings/24/11/41790530/hubspot-shares-climb-after-strong-q3-results-eps-beat-revenues-beat">guidance above estimates</a>.
HubSpot reported quarterly earnings of $2.22 per share, which beat the analyst consensus estimate of $1.91. Quarterly revenue clocked in at $669.7 million which beat the analyst consensus estimate of $646.9 million and is an increase over sales of $557.55 million from the same period last year.
HubSpot shares jumped 7.9% to $645.11 on Thursday.
Here are some other big stocks recording gains in today's session.
<ul>
<li>AppLovin Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APP#NASDAQ">APP</a>) shares jumped 47% to $247.63 after the company reported better-than-expected third-quarter financial results.</li>
<li>Dutch Bros Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BROS#NYSE">BROS</a>) surged 39% to $48.57 following third-quarter earnings.</li>
<li>Emergent BioSolutions Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EBS#NYSE">EBS</a>) gained 34.8% to $12.40 after the company announced it evaluated the safety and efficacy of its new clinical trial of Brincidofovir in treating Mpox across Africa. PANTHER will conduct a clinical trial under The Leadership of Africa Centres for Disease Control and Prevention.</li>
<li>FARO Technologies, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FARO#NASDAQ">FARO</a>) gained 32.8% to $25.07 following third-quarter results.</li>
<li>Under Armour, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UAA#NYSE">UAA</a>) gained 32.7% to $11.61 after the company reported better-than-expected quarterly EPS and sales.</li>
<li>Lyft, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LYFT#NASDAQ">LYFT</a>) gained 28.2% to $18.46 after the company reported better-than-expected quarterly financial results.</li>
<li>Freshworks Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FRSH#NASDAQ">FRSH</a>) jumped 26.2% to $16.51 following upbeat quarterly results.</li>
<li>Wolverine World Wide, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WWW#NYSE">WWW</a>) jumped 26.2% to $20.25 following strong quarterly results.</li>
<li>Zillow Group, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZG#NASDAQ">ZG</a>) gained 22.4% to $68.66 after the company reported better-than-expected quarterly financial results.</li>
<li>IonQ, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IONQ#NYSE">IONQ</a>) rose 21.4% to $19.98 following third-quarter results.</li>
<li>Clearwater Analytics Holdings, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CWAN#NYSE">CWAN</a>) gained 20.9% to $34.56 following better-than-expected quarterly earnings.</li>
<li>Hanesbrands Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HBI#NYSE">HBI</a>) gained 17% to $8.32 following upbeat earnings.</li>
<li>e.l.f. Beauty, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ELF#NYSE">ELF</a>) rose 16% to $120.80 following stronger-than-expected quarterly earnings.</li>
<li>Guardant Health, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GH#NASDAQ">GH</a>) gained 15.5% to $29.20 after the company reported better-than-expected third-quarter financial results and raised its FY24 revenue guidance above estimates.</li>
<li>Kyndryl Holdings, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KD#NYSE">KD</a>) gained 15.3% to $27.81 after reporting upbeat quarterly results.</li>
<li>Warner Bros. Discovery, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WBD#NYSE">WBD</a>) surged 14.7% to $9.61 following third-quarter earnings.</li>
<li>EPAM Systems, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EPAM#NYSE">EPAM</a>) gained 13.7% to $230.60 after the company reported better-than-expected third-quarter financial results and issued FY24 guidance above estimates.</li>
<li>McKesson Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MCK#NYSE">MCK</a>) rose 10.4% to $606.61 as the company reported better-than-expected second-quarter financial results.</li>
<li>Mobileye Global Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MBLY#NASDAQ">MBLY</a>) gained 9.7% to $16.95.</li>
<li>The Estée Lauder Companies Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EL#NYSE">EL</a>) gained 6.6% to $67.46.</li>
<li>Arm Holdings plc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ARM#NYSE">ARM</a>) gained 5.4% to $152.43 following second-quarter results.</li>
</ul>
Now Read This:<a href="https://www.benzinga.com/trading-ideas/long-ideas/24/11/41806634/jim-cramer-recommends-buying-this-utilities-stock-says-no-to-xp"> </a>
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/24/11/41806634/jim-cramer-recommends-buying-this-utilities-stock-says-no-to-xp">Jim Cramer Recommends Buying This Utilities Stock, Says No To XP</a></li>
</ul>

News

Intraday Update

Movers

BROS

CWAN

EPAM

FARO

FRSH

HUBS

IONQ

LYFT

MBLY

HubSpot Posts Better-Than-Expected Results, Joins Under Armour, Lyft, Wolverine World Wide, Zillow And Other Big Stocks Moving Higher On Thursday

McKesson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MCK#NYSE">MCK</a>) reported better-than-expected second-quarter financial <a href="https://www.benzinga.com/quote/MCK/earnings">results on Wednesday</a>.
McKesson reported quarterly earnings of $7.07 per share which beat the analyst consensus estimate of $6.88 per share. The company reported quarterly sales of $93.70 billion which beat the analyst consensus estimate of $89.33 billion.
McKesson shares gained 4.6% to close at $549.31 on Wednesday.
These analysts made changes to their price targets on McKesson following earnings announcement.
<ul>
<li><a href="https://www.benzinga.com/analyst-stock-ratings/analyst/58933b2043eaaa0001698f4c/eric-coldwell">Baird analyst Eric Coldwell</a> upgraded McKesson from Neutral to Outperform and raised the price target from $531 to $688.</li>
<li><a href="https://www.benzinga.com/analyst-stock-ratings/analyst/5ece538c4a1e100001de8a1a/elizabeth-anderson">Evercore ISI Group analyst Elizabeth Anderson </a>maintained McKesson with an Outperform rating and raised the price target from $560 to $680.</li>
</ul>
Considering buying MCK stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="557" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/07090618/image-78-1024x557.png" alt="" class="wp-image-635361" style="width:585px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/07090618/image-78-1024x557.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/07090618/image-78-300x163.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/07090618/image-78-768x418.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/07090618/image-78.png 1216w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read More: 
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/24/11/41806634/jim-cramer-recommends-buying-this-utilities-stock-says-no-to-xp">Jim Cramer Recommends Buying This Utilities Stock, Says No To XP</a></li>
</ul>

Earnings

Price Target

Analyst Ratings

Trading Ideas

These Analysts Boost Their Forecasts On McKesson Following Upbeat Earnings

Evercore ISI Group analyst Elizabeth Anderson maintains McKesson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MCK#NYSE">MCK</a>) with a Outperform and raises the price target from $560 to $680.

Evercore ISI Group Maintains Outperform on McKesson, Raises Price Target to $680

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul>
<li>Piper Sandler boosted Duolingo, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DUOL#NASDAQ">DUOL</a>) price target from $271 to $351. Piper Sandler analyst Arvind Ramnani maintained an Overweight rating. Duolingo shares closed at $318.85 on Wednesday. See how other analysts view this stock.</li>
<li>B of A Securities cut the price target for Bloom Energy Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BE#NYSE">BE</a>) from $8 to $7. B of A Securities analyst Julien Dumoulin-Smith maintained an Underperform rating. Bloom Energy shares closed at $10.97 on Wednesday. <a href="https://www.benzinga.com/quote/BE/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Needham raised the price target for Vertex, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VERX#NASDAQ">VERX</a>) from $45 to $60. Needham analyst Joshua Reilly maintained a Buy rating. Vertex shares closed at $49.76 on Wednesday. <a href="https://www.benzinga.com/quote/VERX/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Baird increased McKesson Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MCK#NYSE">MCK</a>) price target from $531 to $688. Baird analyst Eric Coldwell upgraded the stock from Neutral to Outperform. McKesson shares settled at $549.31 on Wednesday. <a href="https://www.benzinga.com/quote/BROS/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>TD Cowen raised Dutch Bros Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BROS#NYSE">BROS</a>) price target from $47 to $53. TD Cowen analyst Andrew Charles maintained a Buy rating. Dutch Bros shares closed at $34.94 on Wednesday. <a href="https://www.benzinga.com/quote/BROS/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Truist Securities cut Devon Energy Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DVN#NYSE">DVN</a>) price target from $49 to $43. Truist Securities analyst Neal Dingmann downgraded the stock from Buy to Hold. Devon Energy shares closed at $40.02 on Wednesday. <a href="https://www.benzinga.com/quote/DVN/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Cantor Fitzgerald raised the price target for Sarepta Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SRPT#NASDAQ">SRPT</a>) from $152 to $167. Cantor Fitzgerald analyst Kristen Kluska upgradd the stock from Neutral to Overweight. Sarepta shares settled at $127.97 on Wednesday. <a href="https://www.benzinga.com/quote/SRPT/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Leerink Partners raised Zymeworks Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZYME#NASDAQ">ZYME</a>) price target from $10 to $25. Leerink Partners analyst Andrew Berens upgraded the stock from Market Perform to Outperform. Zymeworks shares closed at $15.61 on Wednesday. <a href="https://www.benzinga.com/quote/MSFT/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Loop Capital slashed the price target for Crocs, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CROX#NYSE">CROX</a>) from $150 to $110. Loop Capital analyst Laura Champine downgraded the stock from Buy to Hold. Crocs shares closed at $102.74 on Wednesday. <a href="https://www.benzinga.com/quote/CROX/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Keefe, Bruyette &amp; Woods increased Lemonade, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LMND#NYSE">LMND</a>) price target from $18 to $21. Keefe, Bruyette &amp; Woods analyst Thomas McJoynt-Griffith downgraded the stock from Market Perform to Underperform. Lemonade shares closed at $29.29 on Wednesday. <a href="https://www.benzinga.com/quote/LMND/analyst-ratings">See how other analysts view this stock</a>.</li>
</ul>
Read More: 
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/24/11/41776764/jim-cramer-this-financial-stock-is-a-buy-likes-broadcom">Jim Cramer: This Financial Stock Is A Buy, Likes Broadcom</a></li>
</ul>

Pre-Market Outlook

CROX

DUOL

LMND

SRPT

VERX

ZYME

Sarepta Therapeutics To Rally Around 30%? Here Are 10 Top Analyst Forecasts For Thursday

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul>
<li><a href="https://www.benzinga.com/analyst-stock-ratings/analyst/58933b2043eaaa0001698f4c/eric-coldwell">Baird analyst Eric Coldwell</a> upgraded the rating for McKesson Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MCK#NYSE">MCK</a>) from Neutral to Outperform and raised the price target from $531 to $688. McKesson shares closed at $549.31 on Wednesday. <a href="https://www.benzinga.com/quote/MCK/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Raymond James analyst Ric Prentiss upgraded United States Cellular Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/USM#NYSE">USM</a>) from Market Perform to Outperform and announced a price target of $86. United States Cellular shares closed at $65.15 on Wednesday. <a href="https://www.benzinga.com/quote/USM/analyst-ratings">See how other analysts view this stock</a>.</li>
<li><a href="https://www.benzinga.com/analyst-stock-ratings/analyst/5e00b6e13513fb0001f03e9b/kristen-kluska">Cantor Fitzgerald analyst Kristen Kluska</a> upgraded the rating for Sarepta Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SRPT#NASDAQ">SRPT</a>) from Neutral to Overweight and boosted the price target from $152 to $167. Sarepta Therapeutics shares closed at $127.97 on Wednesday. <a href="https://www.benzinga.com/quote/SRPT/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>JP Morgan analyst Alexei Gogolev upgraded Clearwater Analytics Holdings, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CWAN#NYSE">CWAN</a>) from Neutral to Overweight and raised the price target from $23 to $33. Clearwater Analytics shares closed at $28.58 on Wednesday. <a href="https://www.benzinga.com/quote/CWAN/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Wells Fargo analyst Steven Cahall upgraded the rating for Sinclair, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SBGI#NASDAQ">SBGI</a>) from Underweight to Equal-Weight and increased the price target from $13 to $19. Sinclair shares closed at $17.41 on Wednesday. <a href="https://www.benzinga.com/quote/SBGI/analyst-ratings">See how other analysts view this stock.</a></li>
</ul>
Considering buying MCK stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="562" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/07075449/image-75-1024x562.png" alt="" class="wp-image-635130" style="width:629px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/07075449/image-75-1024x562.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/07075449/image-75-300x165.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/07075449/image-75-768x421.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/07075449/image-75.png 1216w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next:<a href="https://www.benzinga.com/trading-ideas/long-ideas/24/11/41776764/jim-cramer-this-financial-stock-is-a-buy-likes-broadcom"> </a>
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/24/11/41776764/jim-cramer-this-financial-stock-is-a-buy-likes-broadcom">Jim Cramer: This Financial Stock Is A Buy, Likes Broadcom</a></li>
</ul>

Upgrades

SBGI

This McKesson Analyst Turns Bullish; Here Are Top 5 Upgrades For Thursday

WIIM

McKesson shares are trading higher after the company reported better-than-expected Q2 financial results.

Baird analyst Eric Coldwell upgrades McKesson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MCK#NYSE">MCK</a>) from Neutral to Outperform and raises the price target from $531 to $688.

Baird Upgrades McKesson to Outperform, Raises Price Target to $688

Guidance

CORRECTION: McKesson Raises FY25 Adj EPS From $31.75-$32.55 To $32.40-$33.00 Vs $31.99 Est.

McKesson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MCK#NYSE">MCK</a>) reported quarterly earnings of $7.07 per share which beat the analyst consensus estimate of $6.88 by 2.76 percent. The company reported quarterly sales of $93.70 billion which beat the analyst consensus estimate of $89.33 billion by 4.89 percent. This is a 21.35 percent increase over sales of $77.22 billion the same period last year.

Earnings Beats

McKesson Q2 2025 Adj EPS $7.07 Beats $6.88 Estimate, Sales $93.70B Beat $89.33B Estimate

McKesson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MCK#NYSE">MCK</a>) has outperformed the market over the past 20 years by 7.25% on an annualized basis producing an average annual return of 15.46%. Currently, McKesson has a market capitalization of $68.44 billion. 
Buying $1000 In MCK: If an investor had bought $1000 of MCK stock 20 years ago, it would be worth $17,831.98 today based on a price of $527.67 for MCK at the time of writing.
<h3>McKesson's Performance Over Last 20 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1730748630_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

If You Invested $1000 In This Stock 20 Years Ago, You Would Have $18,000 Today

Investors with a lot of money to spend have taken a bullish stance on McKesson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MCK#NYSE">MCK</a>).
And retail traders should know.
We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga.
Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with MCK, it often means somebody knows something is about to happen.
So how do we know what these investors just did? 
Today, <a href="https://pro.benzinga.com/?utm_source=insights">Benzinga</a>'s options scanner spotted 20 uncommon options trades for McKesson.
This isn't normal.
The overall sentiment of these big-money traders is split between 65% bullish and 35%, bearish.
Out of all of the special options we uncovered, 8 are puts, for a total amount of $538,721, and 12 are calls, for a total amount of $842,156.
<h3>Projected Price Targets</h3>
Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $450.0 to $520.0 for McKesson during the past quarter. 
<h3>Volume &amp; Open Interest Development</h3>
In terms of liquidity and interest, the mean open interest for McKesson options trades today is 166.17 with a total volume of 3,049.00.
In the following chart, we are able to follow the development of volume and open interest of call and put options for McKesson's big money trades within a strike price range of $450.0 to $520.0 over the last 30 days.
<h3>McKesson Option Activity Analysis: Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1730315752_0.png" alt="Options Call Chart" />
<h3>Significant Options Trades Detected:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th style="text-align: right;">Open Interest</th>
<th style="text-align: right;">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>MCK</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>11/08/24</td>
<td>$13.8</td>
<td>$11.2</td>
<td>$11.2</td>
<td>$510.00</td>
<td>$253.1K</td>
<td style="text-align: right;">763</td>
<td style="text-align: right;">250</td>
</tr>
<tr>
<td>MCK</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>11/08/24</td>
<td>$12.8</td>
<td>$12.0</td>
<td>$12.7</td>
<td>$507.50</td>
<td>$158.8K</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">125</td>
</tr>
<tr>
<td>MCK</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>02/21/25</td>
<td>$15.8</td>
<td>$14.8</td>
<td>$14.8</td>
<td>$450.00</td>
<td>$106.5K</td>
<td style="text-align: right;">7</td>
<td style="text-align: right;">72</td>
</tr>
<tr>
<td>MCK</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>02/21/25</td>
<td>$15.9</td>
<td>$12.9</td>
<td>$14.7</td>
<td>$450.00</td>
<td>$94.0K</td>
<td style="text-align: right;">7</td>
<td style="text-align: right;">136</td>
</tr>
<tr>
<td>MCK</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>02/21/25</td>
<td>$15.7</td>
<td>$14.3</td>
<td>$14.6</td>
<td>$450.00</td>
<td>$87.6K</td>
<td style="text-align: right;">7</td>
<td style="text-align: right;">196</td>
</tr>
</tbody>
</table>

<h3>About McKesson</h3>
McKesson Corp is one of three leading pharmaceutical wholesalers in the us engaged in sourcing and distributing branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail order), hospitals networks, and healthcare providers. Along with Cencora and Cardinal Health, the three account for over 90% of the us pharmaceutical wholesale industry. Outside the us market, McKesson engages in pharmaceutical wholesale and distribution in Canada. Additionally, the company supplies medical-surgical products and equipment to healthcare facilities and provides a variety of technology solutions for pharmacies.
In light of the recent options history for McKesson, it's now appropriate to focus on the company itself. We aim to explore its current performance.
<h3>Current Position of McKesson</h3>
<ul>
<li>Currently trading with a volume of 455,253, the MCK's price is up by 0.02%, now at $499.28. </li>
<li>RSI readings suggest the stock is currently may be approaching overbought.</li>
<li>Anticipated earnings release is in 7 days.</li>
</ul>
<h3>What Analysts Are Saying About McKesson</h3>
In the last month, 1 experts released ratings on this stock with an average target price of $630.0.
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; An analyst from Leerink Partners persists with their Outperform rating on McKesson, maintaining a target price of $630. 
Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.
If you want to stay updated on the latest options trades for McKesson, <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> gives you real-time options trades alerts.

What the Options Market Tells Us About McKesson

McKesson's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MCK#NYSE">MCK</a>) short percent of float has fallen 12.43% since its last report. The company recently reported that it has 2.10 million shares sold short, which is 1.62% of all regular shares that are available for trading. Based on its trading volume, it would take traders 2.52 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>McKesson Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1730226618_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for McKesson has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing McKesson's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, McKesson's peer group average for short interest as a percentage of float is 5.61%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

How Is The Market Feeling About McKesson?

<a href="https://www.mckesson.com/about-mckesson/newsroom/press-releases/2024/ontada-collaborates-with-microsoft-to-transform-unstructured-oncology-data-with-azure-openai-technology/" title="https://www.mckesson.com/about-mckesson/newsroom/press-releases/2024/ontada-collaborates-with-microsoft-to-transform-unstructured-oncology-data-with-azure-openai-technology/">https://www.mckesson.com/about-mckesson/newsroom/press-releases/2024/ontada-collaborates-with-microsoft-to-transform-unstructured-oncology-data-with-azure-openai-technology/</a>

MSFT

'Ontada Collaborates with Microsoft to Transform Unstructured Oncology Data with Azure OpenAI Technology' - McKesson

McKesson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MCK#NYSE">MCK</a>) has outperformed the market over the past 5 years by 15.56% on an annualized basis producing an average annual return of 29.57%. Currently, McKesson has a market capitalization of $65.46 billion. 
Buying $100 In MCK: If an investor had bought $100 of MCK stock 5 years ago, it would be worth $376.34 today based on a price of $504.67 for MCK at the time of writing.
<h3>McKesson's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1728572437_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

$100 Invested In This Stock 5 Years Ago Would Be Worth $400 Today

Leerink Partners analyst Michael Cherny maintains McKesson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MCK#NYSE">MCK</a>) with a Outperform and lowers the price target from $665 to $630.

Leerink Partners Maintains Outperform on McKesson, Lowers Price Target to $630

At many points in September, investors heard about the S&amp;P 500 hitting a record high. But at several points in that month, the index pulled back instead of moving higher. This is called a resistance level, a technical point where buying activity weakens, leaving room for sellers to come in.&nbsp;
You&#39;re well aware of this price movement if you&#39;re invested in an exchange-traded fund (ETF) such as the&nbsp;SPDR S&amp;P 500 ETF Trust. The SPY is up just 0.29% in the 30 days ending October 1. &nbsp;
But if you&#39;re investing in individual stocks, this choppy price action can be an opportunity to look for stocks with strong fundamentals that are being overlooked by investors. These are the stocks that have the best opportunity for strong gains. To find this group of stocks, we used the MarketBeat stock screener to find S&amp;P 500 stocks trading within 30% of their 52-week low with a forecast for at least 10% upside in earnings in the next 12 months. &nbsp;
<h2>A Breakout Stock in a Breakout Sector&nbsp;</h2>
SLB Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/slb#NYSE">SLB</a>), formerly known as Schlumberger, is an oilfield services company. The company&#39;s revenue and earnings are less sensitive to the price of crude oil but&nbsp;highly sensitive to CAPEX spending. In the last year, many of the major oil companies have been making up for years of underspending as the price of oil has moved higher. &nbsp;
That&#39;s reflected in the company&#39;s last four quarters, in which they reported year-over-year double-digit revenue and earnings growth. The price of oil is likely to continue climbing in 2025 regardless of the outcome of November&#39;s election, which makes SLB stock and its 2.5% dividend yield attractive, particularly with the stock trading near two-year lows. &nbsp;
The SLB analyst forecast on MarketBeat gives the stock a consensus price target of $65.29, which gives investors the potential for 48.5% upside from the stock&#39;s closing price on October 1, 2024. &nbsp;
<h2>This Lithium Stock Is a Solid Play as China Stocks Soar&nbsp;</h2>
China stocks are making a strong recovery as the Chinese government has unleashed a wave of stimulus programs to boost the country&#39;s struggling economy. If you believe in the economy&#39;s recovery, it bodes well for electric vehicle (EV) sales. &nbsp;
However, many investors may still feel that it&#39;s too risky to buy China stocks. A company that is adjacent to China stocks is Albemarle Corp. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/alb#NYSE">ALB</a>). The lithium miner&#39;s stock is down over 34% in 2024 as the price of lithium has declined as has the company&#39;s free cash flow. &nbsp;
Albemarle&#39;s turnaround may not be immediate, which explains the consensus Hold rating on the stock. However, ALB stock looks to be forming a bottom around $72. And the Albermarle analyst forecasts on MarketBeat give the stock a $117.10 price target which is 26% higher than its price on October 2. And investors get a dividend that the company has been increasing for 30 consecutive years. &nbsp;
<h2>Despite Supply Chain Concerns, This Undervalued Medical Stock Is Worth a Look&nbsp;</h2>
McKesson Corp. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/mck#NYSE">MCK</a>) is one of the undervalued medical stocks in the S&amp;P 500. The company is a global leader in healthcare that partners with care providers, pharmacies, and manufacturers to deliver the right medicines, products and healthcare services to the right patients at the right time. &nbsp;
MCK stock is up 7.6% in 2024 but is down approximately 14.7% in the last three months. The company last reported earnings in August and missed on the top line. One issue affecting the company is delays in getting GLP-1 drugs. Demand simply outpaces supply. &nbsp;
To be fair, this issue is likely to get worse if the port strike lasts for any length of time. That could weigh on MCK stock in the short term. &nbsp;
However, analysts are still forecasting a 10% increase in the company&#39;s earnings. They also give the stock a consensus Moderate Buy rating with a price target of over $613, which is more than 24% above its current price. Investors also get a dividend that has increased at an average rate of 11% in the last three years. The company may increase the payout now that it is done buying back its shares. &nbsp;
The article &quot;<a href="https://www.marketbeat.com/stock-ideas/has-the-s-and-p-500-hit-resistance-level-stocks-to-buy-on-a-dip/">S&amp;P 500 Hitting Resistance: These 3 Stocks Offer the Best Upside</a>&quot; first appeared on MarketBeat.

Dividends

S&P 500 Hitting Resistance: These 3 Stocks Offer the Best Upside

McKesson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MCK#NYSE">MCK</a>) has outperformed the market over the past 15 years by 3.02% on an annualized basis producing an average annual return of 15.04%. Currently, McKesson has a market capitalization of $61.95 billion. 
Buying $1000 In MCK: If an investor had bought $1000 of MCK stock 15 years ago, it would be worth $8,020.07 today based on a price of $477.60 for MCK at the time of writing.
<h3>McKesson's Performance Over Last 15 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1727287225_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Here's How Much You Would Have Made Owning McKesson Stock In The Last 15 Years

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Ultragenyx Pharmaceutical (RARE – Research Report)...

Analysts Conflicted on These Healthcare Names: Ultragenyx Pharmaceutical (RARE), Henry Schein (HSIC) and McKesson (MCK)

In a report released today, Stephanie Davis from Barclays maintained a Buy rating on McKesson (MCK – Research Report), with a price target of $668....

Barclays Remains a Buy on McKesson (MCK)

In a report released today, Eric Coldwell from Robert W. Baird upgraded McKesson (MCK – Research Report) to a Buy, with a price target of $688.00. ...

McKesson's Positive Trajectory Reinforces Buy Rating Amid Strong Financial Performance and Strategic Growth

Baird upgraded McKesson (MCK) to Outperform from Neutral with a price target of $688, up from $531. The firm says McKesson cleared up several of it...

McKesson upgraded to Outperform from Neutral at Baird

Steve Baxter, an analyst from Wells Fargo, maintained the Hold rating on McKesson (MCK – Research Report). The associated price target remains the ...

McKesson's Strong Q2 Performance Leads to Upward EPS Revision, But Hold Rating Due to Segment Concerns and Uncertain Long-Term Growth

Morgan Stanley analyst Erin Wright has maintained their bullish stance on MCK stock, giving a Buy rating today. Erin Wright has given his Buy ratin...

McKesson's Strong Financial Performance and Strategic Initiatives Justify Buy Rating

McKesson (MCK – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Allen Lutz from Bank of ...

McKesson: Strong Q2 Performance and Raised FY 2025 Guidance Justify Buy Rating

In a report released today, Elizabeth Anderson CFA from Evercore ISI maintained a Buy rating on McKesson (MCK – Research Report), with a price targ...

McKesson (MCK) Gets a Buy from Evercore ISI

The most talked about and market moving research calls around Wall Street are now in one place. Here are today's research calls that investors need...

JPMorgan, Five Below downgraded: Wall Street's top analyst calls

Notable gainers among liquid option names this morning include EPAM Systems (EPAM) $233.69 +31.00, Warner Bros. Discovery (WBD) $9.52 +1.14, Viatri...

Comments

McKesson

空売り

McKesson (NYSE:MCK) 株価情報, 空売り情報

こんな人も見ています

ニュース

パートナーシップ

ベンジンガ・グローバル